CN102746239B - 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 - Google Patents

治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 Download PDF

Info

Publication number
CN102746239B
CN102746239B CN201210157072.8A CN201210157072A CN102746239B CN 102746239 B CN102746239 B CN 102746239B CN 201210157072 A CN201210157072 A CN 201210157072A CN 102746239 B CN102746239 B CN 102746239B
Authority
CN
China
Prior art keywords
alkyl
compound
amino
independently selected
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210157072.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102746239A (zh
Inventor
R·瓦格纳
M·D·图法诺
K·D·斯特沃特
T·W·罗克威
J·T·兰多尔夫
J·K·普拉特
C·E·莫特
C·J·马林
K·L·朗格尼克
Y·刘
D·刘
A·C·克鲁格
W·M·卡蒂
D·K·赫琴森
P·P·黄
C·A·弗伦特奇
P·L·唐纳
D·A·德戈伊
D·A·贝特本纳
D·M·巴恩斯
S·陈
T·S·弗兰齐克二世
Y·高
A·R·海格特
J·E·亨格维尔德
R·F·亨里
B·J·科特克基
X·楼
K·萨里斯
G·G·Z·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories Ltd
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102746239(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN102746239A publication Critical patent/CN102746239A/zh
Application granted granted Critical
Publication of CN102746239B publication Critical patent/CN102746239B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
CN201210157072.8A 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 Expired - Fee Related CN102746239B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US60/972,877 2007-09-17
US60/972877 2007-09-17
US9679108P 2008-09-13 2008-09-13
US61/096791 2008-09-13
US61/096,791 2008-09-13
CN200880107764.3A CN101801935B (zh) 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880107764.3A Division CN101801935B (zh) 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN102746239A CN102746239A (zh) 2012-10-24
CN102746239B true CN102746239B (zh) 2016-02-10

Family

ID=39948002

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210157072.8A Expired - Fee Related CN102746239B (zh) 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN200880107764.3A Expired - Fee Related CN101801935B (zh) 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880107764.3A Expired - Fee Related CN101801935B (zh) 2007-09-17 2008-09-17 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Country Status (30)

Country Link
US (3) US8415351B2 (enExample)
EP (2) EP2222646B1 (enExample)
JP (2) JP5734654B2 (enExample)
KR (2) KR101660360B1 (enExample)
CN (2) CN102746239B (enExample)
AR (2) AR070027A1 (enExample)
AU (1) AU2008302448B2 (enExample)
BR (1) BRPI0816994B8 (enExample)
CA (2) CA2976793A1 (enExample)
CL (2) CL2008002794A1 (enExample)
CO (1) CO6260076A2 (enExample)
CR (2) CR11316A (enExample)
DO (2) DOP2010000084A (enExample)
ES (1) ES2453591T3 (enExample)
GT (1) GT201000061A (enExample)
IL (1) IL204547A (enExample)
IN (1) IN2012DN05113A (enExample)
MX (2) MX2010002905A (enExample)
MY (1) MY162760A (enExample)
NZ (3) NZ618277A (enExample)
PA (1) PA8796201A1 (enExample)
PE (2) PE20130209A1 (enExample)
PH (1) PH12013500365A1 (enExample)
RU (2) RU2543620C2 (enExample)
SG (1) SG183733A1 (enExample)
TW (2) TWI534137B (enExample)
UA (1) UA117800C2 (enExample)
UY (1) UY31344A1 (enExample)
WO (1) WO2009039127A1 (enExample)
ZA (2) ZA201204223B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628654A (zh) 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2334662A1 (en) 2008-09-26 2011-06-22 F. Hoffmann-La Roche AG Pyrine or pyrazine derivatives for treating hcv
RU2524573C2 (ru) * 2009-03-24 2014-07-27 Эбботт Лэборетриз Способ получения (e)-n-(3-трет-бутил-5-(2,4-диоксо-3,4-дигидропиримидин-1(2н)-ил)-2-метокси-стирил)фенил)метансульфонамида и промежуточные соединения для его получения
RU2552533C2 (ru) * 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
JP2012522013A (ja) * 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
SG176976A1 (en) * 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
BR112012014299A2 (pt) * 2009-12-14 2016-07-05 Hoffmann La Roche composto de antivírus heterocíclicos
US9216952B2 (en) * 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
BR112013000245A2 (pt) 2010-07-07 2016-05-24 Hoffmann La Roche compostos antivirais heterocíclicos
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
EP3461556A1 (en) 2010-07-16 2019-04-03 AbbVie Ireland Unlimited Company Phosphine ligands for catalytic reactions
EP3056486B1 (en) * 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
CN103068819B (zh) 2010-08-13 2014-08-13 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
TWI558400B (zh) 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
SG10201602384VA (en) * 2011-03-31 2016-05-30 Konstanze Schäfer Perfluorinated compounds for the non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
US9040516B2 (en) 2011-08-01 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
CN104334529B (zh) 2012-05-15 2017-03-15 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
JP6078639B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
EA201492005A1 (ru) 2012-05-15 2015-04-30 Новартис Аг Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
JP2015522022A (ja) 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
EP2887941B1 (en) 2012-08-21 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
JP6266635B2 (ja) * 2012-10-18 2018-01-24 アッヴィ・インコーポレイテッド ピリミジンジオン誘導体化合物の製剤
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
WO2015002952A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
BR112016000241B1 (pt) 2013-07-08 2021-06-22 Bayer Cropscience Aktiengesellschaft Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
WO2017087608A1 (en) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
KR20200053481A (ko) 2017-07-24 2020-05-18 비타이 파마슈티컬즈, 엘엘씨 RORγ의 억제제
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
JP7785663B2 (ja) * 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (enExample) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167954A (en) * 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AR061570A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
CN104628654A (zh) 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN105693626A (zh) * 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《Bromo derivatives of 1-(4-hydroxyphenyl) dihydrouracil and 1-(4-hydroxyphenyl)-5-or-6-metehyldihydrouracils》;R.S.Baltrushis et al;《CHEMISTRY OF HETEROCYCLIC COMPOUNDS》;19821231;第18卷(第9期);第1251-1254页 *
《Efficient N-Arylation and N-Alkenylation of the Five DNA/RNA Nucleobases》;Mikkel F. Jacobsen et al;《 J.Org.Chem》;20061231;第9183-9190页 *

Also Published As

Publication number Publication date
MX2010002905A (es) 2010-07-05
IN2012DN05113A (enExample) 2015-10-23
US8685991B2 (en) 2014-04-01
IL204547A (en) 2016-04-21
KR20100068289A (ko) 2010-06-22
NZ600371A (en) 2014-07-25
SG183733A1 (en) 2012-09-27
US20110070193A1 (en) 2011-03-24
RU2010114828A (ru) 2011-10-27
HK1147256A1 (en) 2011-08-05
TWI437994B (zh) 2014-05-21
PH12013500365A1 (en) 2014-09-08
EP2222646A1 (en) 2010-09-01
CN101801935A (zh) 2010-08-11
TWI534137B (zh) 2016-05-21
AU2008302448B2 (en) 2014-11-06
CN101801935B (zh) 2014-12-03
AR070027A1 (es) 2010-03-10
KR20150117632A (ko) 2015-10-20
CL2008002794A1 (es) 2009-09-04
KR101660360B1 (ko) 2016-09-27
CN102746239A (zh) 2012-10-24
PE20090705A1 (es) 2009-07-17
CO6260076A2 (es) 2011-03-22
MY162760A (en) 2017-07-14
IL204547A0 (en) 2010-11-30
JP2010539186A (ja) 2010-12-16
US8415351B2 (en) 2013-04-09
US9095590B2 (en) 2015-08-04
KR101552474B1 (ko) 2015-09-11
UY31344A1 (es) 2009-04-30
ZA201204223B (en) 2015-12-23
NZ618277A (en) 2015-07-31
BRPI0816994B8 (pt) 2021-05-25
CA2976793A1 (en) 2009-03-26
CA2699981A1 (en) 2009-03-26
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
PA8796201A1 (es) 2009-04-23
TW200918066A (en) 2009-05-01
DOP2010000396A (es) 2013-12-31
MX338555B (es) 2016-04-20
RU2013104270A (ru) 2014-08-10
UA117800C2 (uk) 2018-10-10
RU2599635C2 (ru) 2016-10-10
AR087472A2 (es) 2014-03-26
US20120213733A1 (en) 2012-08-23
GT201000061A (es) 2012-03-26
JP5734654B2 (ja) 2015-06-17
PE20130209A1 (es) 2013-03-24
NZ584720A (en) 2012-07-27
DOP2010000084A (es) 2010-06-15
BRPI0816994B1 (pt) 2019-12-24
CL2013000372A1 (es) 2013-10-04
AU2008302448A1 (en) 2009-03-26
CA2699981C (en) 2017-08-22
EP2222646B1 (en) 2014-01-22
WO2009039127A1 (en) 2009-03-26
BRPI0816994A2 (pt) 2015-03-24
RU2543620C2 (ru) 2015-03-10
CR20150238A (es) 2015-07-01
ES2453591T3 (es) 2014-04-08
US20140235638A1 (en) 2014-08-21
TW201443027A (zh) 2014-11-16
ZA201204224B (en) 2015-12-23
JP2013049681A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
CN102746239B (zh) 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102746240B (zh) 抗感染嘧啶及其用途
CN101918369B (zh) 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
AU2014280939B2 (en) Uracil or thymine derivative for treating hepatitis C
HK1148273B (en) Anti-infective pyrimidines and uses thereof
HK1177457A (en) Anti-infective pyrimidines and uses thereof
HK1177457B (en) Anti-infective pyrimidines and uses thereof
AU2013202002A1 (en) Uracil or thymine derivative for treating hepatitis C
HK1189590B (en) Anti-infective pyrimidines and uses thereof
HK1156033B (en) Anti-infective pyrimidines and uses thereof
HK1189590A (en) Anti-infective pyrimidines and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBOTT HOSPITAL CO., LTD.

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20131211

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Bahamas Nassau

Applicant after: AbbVie Inc.

Address before: Bahamas Nassau

Applicant before: Abbott Laboratories Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ABBOTT HOSPITAL CO., LTD. TO: ABBVIE BAHAMAS B.V.

TA01 Transfer of patent application right

Effective date of registration: 20131211

Address after: Bahamas Nassau

Applicant after: Abbott Laboratories Ltd.

Address before: Illinois State

Applicant before: ABBOTT LABORATORIES

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160210

Termination date: 20200917